Introduction {#s1}
============

*Mycoplasma hyopneumoniae* is the primary agent involved in porcine enzootic pneumonia. Infections with *M hyopneumoniae* are highly prevalent in almost all swine-producing areas, causing significant economic losses to the pig industry worldwide ([@R17]). Control of *M hyopneumoniae* infections can be accomplished in several ways, mainly by optimisation of management practices and the use of antimicrobials and vaccines ([@R8]). However, the protection induced with current *M hyopneumoniae* bacterins is incomplete because these vaccines do not prevent colonisation ([@R4]).

On the one hand, a wide range of *M hyopneumoniae* vaccines are currently commercially available, and most of them, if not all, are bacterins. Although previous studies have evaluated pig immunisation using either homologous and heterologous vaccines ([@R21]) or protective efficacy against high-virulence and low-virulence *M hyopneumoniae* strains ([@R20]), less is known about virulence and genetic diversity of *M hyopneumoniae* strains used to manufacture bacterins and their relationship with *M hyopneumoniae* field strains. [@R21] mentioned that most of commercial vaccines are based on J strain; however, in a preliminary genetic characterisation of *M hyopneumoniae* bacterins, the authors have found other genetic subtypes of *M hyopneumoniae* in commercial vaccines available in the authors' country ([@R11]).

*M hyopneumoniae* genetic diversity has been reported around the world by using different molecular techniques ([@R13], [@R14]; [@R3]; [@R15]). From all typing techniques, Multiple-Locus Variable number tandem repeat Analysis (MLVA) seems to be a suitable molecular tool to detect *M hyopneumoniae* genetic subtypes ([@R3], [@R22]) since the isolation of the agent is not required as each locus is specifically amplified by PCR.

Due to the lack of information about both the genetic characteristics of commercial vaccines and their relationship with *M hyopneumoniae* field strains, the objective of this study was to identify genetic subtypes of some *M hyopneumoniae* bacterins and to compare them with *M hyopneumoniae* field strains present in the authors' country.

Materials and methods {#s2}
=====================

This work was performed at the Laboratory of Animal Pathology of the Faculty of Agronomy and Veterinary Sciences (UNRC, Río Cuarto, Córdoba, Argentina), according to the international guidelines of the Council for International Organizations of Medical Sciences (CIOMS).

Bacterins and bronchoalveolar lavage DNA {#s2a}
----------------------------------------

Six *M hyopneumoniae* bacterins that are commercialised in Argentina (and also in other countries) were analysed. In order to know the *M hyopneumoniae* strains used for the bacterins, information was retrieved from vaccine manufacturer companies. Bacterins A and D corresponded to strain J, but for bacterins B, C, E and F, no information was available. DNA from the *M hyopneumoniae* bacterins was extracted with a commercial kit (QIAamp Stool Mini Kit, Qiagen) to avoid the interference of possible PCR inhibitors.

In order to compare the allelic profiles of *M hyopneumoniae* bacterins with *M hyopneumoniae* field strains, DNA from 28 bronchoalveolar lavages (BAL) positive for the pathogen were included in the analysis. BAL corresponded to 22-week-old pigs at slaughter from three herds from centre-south of Córdoba province, and DNA was extracted using a commercial kit (DNAzol, Invitrogen) according to the manufacturer's instructions. Before MLVA, DNA from *M hyopneumoniae* bacterins and field strains were tested by a species-specific nested PCR (nPCR; [@R1]) to check that *M hyopneumoniae* DNA was present and able to be amplified by PCR. All the samples rendered positive results.

Multiple-Locus Variable number tandem repeat Analysis {#s2b}
-----------------------------------------------------

The MLVA scheme for the regions *p146R1*, *H4*, *H5* and *p95* was performed according to [@R3]. The amplicons were resolved in 2 per cent agarose gel run at 150 V for 3.5 hours and stained with SYBR Green I (Invitrogen).

Regarding the region *p146R3*, it was analysed by the nPCR developed by [@R15] for the first round of amplification, and the primers and conditions described by [@R9] for the second round. The amplicons were purified (Puriprep-GP Kit, Inbio Highway, Tandil, Argentina), quantified (NanoDrop ND-1000, Thermo Fisher Scientific, Wilmington, Delaware, USA) and sequenced (ABI 3130*xl*; Applied Biosystems, Foster City, California, USA) with the primers used in the second round ([@R9]). The number of serine repeats (encoded by the codons TCT, TCA and TCC) was determined by viewing *p146R3* sequences with the BioEdit software ([@R23]).

Results {#s3}
=======

Different *M hyopneumoniae* genetic subtypes were identified in the analysed samples. All the loci analysed rendered positive results with DNA samples obtained from *M hyopneumoniae* bacterins. In these loci, some alleles were identified among both bacterin and clinical samples ([Fig 1](#VETRECO2015000117F1){ref-type="fig"}), but others were found only within a particular kind of samples ([Table 1](#VETRECO2015000117TB1){ref-type="table"}).

###### 

Alleles identified in each locus in the different samples analysed

                      Herd A   Herd B   Herd C   Bacterins                                                                                                                                                      
  ------------------- -------- -------- -------- ----------- ---- --- ---- ---- ---- --- ---- --- ------- ---- ---- --- ----- ----- ---- ---- ---- --- ---- --- ---- ---- ---- ---- ---- ------- ---- ---- ---- ----
  *P146R1*            --       a        --       a           --   a   --   --   a    a   --   a   --      a    a    a   --    --    --   --   --   a   --   a   --   a    a    --   a    b,c,d   a    --   --   --
  *P146R3* (nested)   g        k        k        k           k    k   k    h    h    h   g    g   g       e    f    g   h     g     h    h    j    i   h    h   i    i    h    h    j    l       l    j    i    l
  *P95*               --       m        --       m           --   m   --   --   --   m   m    m   m,n     --   m    m   m,n   --    --   --   --   m   --   m   --   --   --   --   --   m       --   --   m    m
  *H4*                --       o        --       o           --   o   --   o    o    p   p    p   --      --   --   p   --    --    o    --   --   q   --   p   --   --   o    --   --   q,r,s   --   --   --   --
  *H5*                t        u        --       --          --   u   --   --   --   v   --   v   t,v,w   u    u    u   --    t,v   --   --   --   v   --   v   u    u    u    --   --   u       --   --   --   u

Amplicons sizes (approximately) of probable alleles according to the loci studied: ***p146R1***: allele a (350 bp); allele b (370 bp); allele c (300 bp); allele d (200 bp). ***p146R3***: allele e (10 serines repeat); allele f (12 serines repeat); allele g (14 serines repeat); allele h (16 serines repeat); allele i (17 serines repeat); allele j (18 serines repeat); allele k (19 serines repeat); allele l (21 serines repeat). ***p95***: allele m (280 bp); allele n (350 bp). ***H4***: allele o(640 bp); allele p (700 bp); allele q (750 bp); allele r (370 bp); allele s (190 bp). ***H5***: allele t (more than 1000 bp); allele u (500 bp); allele v (520 bp); allele w (800 bp)

![PCR results for loci *p146R1* (A), *p95* (B), *H4* (C) and *H5* (D). Numbers inside the boxes identify the alleles. MW, DNA ladder with fragments ranging from 100 bp to 1000 bp](vetreco2015000117f01){#VETRECO2015000117F1}

In a few loci were observed more than one allele in the same sample, in the case of a bacterin (locus *p146R1* in bacterin B) and four BAL samples (loci *p95* and *H5* in sample 13; locus *p95* in sample 17; locus *H5* in sample 18).

Many loci could not be amplified in some samples, but *p146R3*, which was the one analysed in an nPCR format, was the only locus able to be amplified in all samples. Therefore, the analysis of that polyserine repeat was feasible in all samples, and revealed that locus *p146R3* was the most polymorphic ([Table 1](#VETRECO2015000117TB1){ref-type="table"}).

Discussion {#s4}
==========

Different *M hyopneumoniae* genetic subtypes, among and within herds and also among bacterin strains, were detected using MLVA. Despite the fact that the characterisation could not be performed for all loci, the results obtained contribute to the knowledge of the genetic diversity of the vaccines most used for pig immunisation against *M hyopneumoniae*, of which, there have been few previous characterisations ([@R7], [@R3]). In the MLVA scheme used in the present study, the region that showed more polymorphism was *p146R3*, followed by *H4*, *H5*, *p146R1* and *p95*. These results are in agreement with those of [@R3] who selected four of these regions to unambiguously discriminate J, 7448, 7422 and PMS *M hyopneumoniae* strains.

Most of the loci could not be amplified in all samples. This could be due to variability in the primer-binding sites or, most probably, to the lower sensitivity of the PCRs used, since the nPCR used for *M hyopneumoniae* detection ([@R1]) and the other for the analysis of *p146R3* locus rendered positive results with all of the 28 DNA samples.

Although [@R3] suggested that developed PCR assays could have sufficient sensitivity for *M hyopneumoniae* typing from clinical samples, a complete characterisation by MLVA is not always possible using conventional PCR, even when working with BAL samples. [@R6] noticed that successful genotyping was dependent on a sufficiently high concentration of *M hyopneumoniae* DNA in lung samples from wild boar. In this regard, the authors have recently reported the need to increase the sensitivity of some of the PCRs used for MLVA typing of this pathogen ([@R16]). Sensitivity could be increased also using touchdown PCR ([@R5]) and/or capillary electrophoresis ([@R22]). This would allow *M hyopneumoniae* typing from minimally invasive samples (such as nasal swabs) without killing animals or performing invasive sampling ([@R16]).

[@R2] reported that they were unable to type *M hyopneumoniae* vaccine strains using PCR-restriction fragment length polymorphism (RFLP) due to the absence of amplification of the *p146* gene. In the present paper, the use of the nPCR format for the *p146R3* locus was shown to be advantageous and allowed the typing from all samples.

Interestingly, in some samples, more than one allele seemed to be present in the same locus. This fact could be due to unspecific primer annealing or to the presence of different *M hyopneumoniae* genotypes in the same sample. An unspecific annealing of the primers is considered highly unlikely. The presence of different genotypes of *M hyopneumoniae* has been reported previously. The authors found two probable alleles present in one pig BAL sample when analysing the locus *H4* from *M hyopneumoniae* in a previous study in the authors' country ([@R15]). Furthermore, [@R22] demonstrated simultaneous infection with multiple *M hyopneumoniae* strains both by the presence of double alleles in the electropherograms of the MLVA loci of clinical samples and by the presence of different strains isolated from the same animals.

According to manufacturer's information, bacterins A and D are based on *M hyopneumoniae* strain J, and the present results are in accordance to that, because *p146R3* region showed a repeat motif with 18 serines, agreeing with previous reports ([@R3], [@R9]) and the available data for that strain in National Center for Biotechnology Information (NCBI) database. For bacterin A, the results for *p146R1* also corresponded to strain J, but, unfortunately, the other variable number tandem repeats could not be analysed due to the presence of null alleles.

Among *M hyopneumoniae* field strains present in the BAL samples, the *p146R3* allele with the 18 serine repeat motif was not identified. Although this allele has not been previously found either in *M hyopneumoniae* field strains from Argentina ([@R15]) or in *M hyopneumoniae* vaccine strains from Brazil ([@R3]), it has been detected in *M hyopneumoniae* field strains from Europe ([@R9], [@R12]). Furthermore, the *M hyopneumoniae* non-pathogenic strain J was isolated from a pig herd in the UK in 1963 ([@R21]), and maybe, this genotype is not present in South America. However, more studies have to be performed to elucidate this.

Regarding bacterins B, C and F, they all showed a 21-serine repeat motif in the *p146R3* analysis. The same number of serine repeats has been reported in the *M hyopneumoniae* strain 232 isolated in the USA and in field strains from Europe and Argentina ([@R10], [@R9], [@R12], [@R15], [@R16]), but not in strains isolated in Brazil ([@R18]) that were analysed by [@R3]. Additionally, bacterins B and F showed the same alleles in *p95* and *H5* regions (500 bp), but bacterin B seems to be made from more than one strain, since three possible alleles were found in each of the two loci (*p146R1* and *H4*). Bacterins B and C could be distinguished with regard to the alleles present at locus *p146R1*.

Although a recent study has pointed out that a locus (which encodes a hypothetical protein) could be associated with *M hyopneumoniae* virulence ([@R2]), at present, a molecular marker able to identify high-virulence and low-virulence *M hyopneumoniae* strains does not exist, and therefore, differences in performance of vaccination in each particular herd cannot be explained that way.

In the present paper, the utility of MLVA for *M hyopneumoniae* typing in clinical samples and bacterins was demonstrated, particularly when a high-sensitivity method such as nPCR is used. Furthermore, the results obtained showed the presence of more than one *M hyopneumoniae* genotype in some pigs and also in one of the bacterins analysed. It is also worth noting that MLVA typing allowed the distinction among circulating field strains and also when comparing them with vaccine strains, which, knowing the relatedness among them, could be useful in the research of the efficacy of the vaccines.
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